Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected.

Published byJari Sala Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected."— Presentation transcript:

1 Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ampicillin; CRO, ceftriaxone. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, dkz173, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Time–kill studies for selected isolates (each line represents the average of duplicate studies). AMP, ... Figure 1. Time–kill studies for selected."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 3 Doctors leaving (Matthews, 2013, p.13.)

Figure 3 Doctors leaving (Matthews, 2013, p.13.)
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1 Qualitative analysis—themes and subthemes regarding detention minimisation Unless provided in the caption above, the following copyright applies.

Figure 1 Qualitative analysis—themes and subthemes regarding detention minimisation Unless provided in the caption above, the following copyright applies.
Figure 1. Variation in population size of the donor strain HN-1 and E

Figure 1. Variation in population size of the donor strain HN-1 and E
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.
Figure 1. SpeI-PFGE dendrogram comparing P

Figure 1. SpeI-PFGE dendrogram comparing P
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
bDMARD: biologic DMARD.

bDMARD: biologic DMARD.
(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.

(A) Upper ... (A) Upper gastroduodenoscopy showing gastric antral vascular ectasia with visible bleeding. (B) Nailfold capillaroscopy showing dilated capillaries.

Similar presentations

Ads by Google